+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Fibrate Drugs Market by Drug Type (Bezafibrate, Ciprofibrate, Fenofibrate), Formulation (Capsules, Oral Suspension, Tablets), Route Of Administration, End User, Distribution Channel, Dosage Strength, Indication - Global Forecast 2025-2030- Product Image
Fibrate Drugs Market by Drug Type (Bezafibrate, Ciprofibrate, Fenofibrate), Formulation (Capsules, Oral Suspension, Tablets), Route Of Administration, End User, Distribution Channel, Dosage Strength, Indication - Global Forecast 2025-2030- Product Image
Sale

Fibrate Drugs Market by Drug Type (Bezafibrate, Ciprofibrate, Fenofibrate), Formulation (Capsules, Oral Suspension, Tablets), Route Of Administration, End User, Distribution Channel, Dosage Strength, Indication - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 182 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6016409
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Fibrate Drugs Market is entering a new phase shaped by evolving clinical demands, competitive innovation, and tightened regulatory scrutiny. Senior leaders require clarity on how therapeutic advances, supply chain challenges, and regional diversity impact both strategy and growth opportunities in this dynamic sector.

Market Snapshot: Fibrate Drugs Market Outlook

The Fibrate Drugs Market grew from USD 3.72 billion in 2024 to USD 3.98 billion in 2025. It is expected to continue growing at a CAGR of 6.93%, reaching USD 5.56 billion by 2030. Demand is underpinned by the central role of fibrate therapeutics in dyslipidemia management, further propelled by a rising incidence of mixed lipid disorders. Innovative delivery approaches and combination regimens are shifting prescribing patterns across geographies. Patent expiries are intensifying generic competition while real-world clinical outcomes and post-marketing data drive decision-making for payers and healthcare systems.

Scope & Segmentation

  • Drug Types: Bezafibrate, Ciprofibrate, Fenofibrate, Gemfibrozil
  • Formulations: Capsules, Oral Suspension, Tablets
  • Route of Administration: Oral
  • End Users: Clinics, Home Care, Hospitals, Retail Pharmacies
  • Distribution Channels: Hospital Pharmacy, Online Pharmacy (Branded Online, Third-Party Platform), Retail Pharmacy (Chain Retail Pharmacy, Independent Retail Pharmacy)
  • Dosage Strengths: 100 mg, 145 mg, 200 mg, 48 mg, 67 mg
  • Indications: Hypercholesterolemia, Hypertriglyceridemia, Mixed Dyslipidemia
  • Regions Covered: Americas (United States—California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, and key Middle Eastern and African markets), Asia-Pacific (China, India, Japan, Australia, and Southeast Asian countries)
  • Leading Producers: Abbott Laboratories, Kowa Pharmaceuticals America, LLC, Teva Pharmaceutical Industries Ltd., Viatris Inc., Sandoz International GmbH, Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Lupin Limited, Zydus Lifesciences Ltd., Torrent Pharmaceuticals Ltd.

Key Takeaways for Decision-Makers

  • Fibrate therapies continue to fill an integral gap in the management of complex lipid profiles, particularly where standard statin treatment is insufficient or contraindicated.
  • Expanding adoption of digital health platforms and AI enables more precise patient segmentation, adherence monitoring, and real-time therapy adjustment.
  • Patent expiries have broadened access to generics, intensifying pricing pressure and creating opportunities for innovative formulation and fixed-dose combinations.
  • Regional market dynamics vary: North America’s emphasis on value-based care contrasts with cost-driven approaches in Southeast Asia and public-driven expansion in the Gulf states.
  • Extended-release and novel oral suspensions are being adopted to address specific patient populations—especially elderly and pediatric groups—while maintaining regulatory compliance and therapeutic effectiveness.
  • Strategic alliances across supply and distribution chains are emerging as levers for competitive differentiation amid continuing tariff volatility and shifting sourcing landscapes.

Tariff Impact on Supply Chains

Recent global tariff adjustments have heightened production costs for active pharmaceutical ingredients within the fibrate drug class. Manufacturers are responding by diversifying sourcing, forming partnerships with API suppliers in Southeast Asia and India, and employing multi-tier vendor strategies. These actions improve resilience and stabilize pricing in the face of trade policy shifts. Streamlined procurement and enhanced inventory planning help reduce the risk of disruption without compromising quality standards.

Methodology & Data Sources

The study draws on a combination of primary interviews with clinical specialists, procurement leaders, and supply chain experts, alongside peer-reviewed literature, regulatory filings, and health authority publications. Rigorous triangulation and statistical validation techniques were applied to ensure findings reflect both clinical realities and market conditions. Data collection processes included double-blind extraction and independent auditing to minimize bias.

Why This Report Matters

  • Empowers senior decision-makers with actionable perspectives on technology-driven care, pricing pressures, and emerging distribution models in the fibrate drugs market.
  • Supports informed planning with segment-specific analysis and regionally nuanced insights, identifying new growth avenues in evolving healthcare environments.
  • Enables organizations to benchmark strategies, assess supply resilience, and align R&D investments with real-world regulatory and patient needs.

Conclusion

The Fibrate Drugs Market is marked by ongoing therapeutic advancement and greater operational complexity. Organizations that embrace adaptable supply chains, leverage digital technologies, and tailor strategies by market will help shape enduring value for both patients and shareholders.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emerging use of fenofibrate in combination therapies for metabolic syndrome management
5.2. Advancements in nanoparticle delivery systems improving fibrate bioavailability and patient adherence
5.3. Increasing off-label prescriptions of bezafibrate for cardiovascular risk reduction in diabetic patients
5.4. Regulatory scrutiny over fenofibrate safety profiles driving post-marketing surveillance initiatives
5.5. Growth in generic fibrate market share fueled by patent expirations and pricing pressures in North America
5.6. Integration of real-world evidence in fibrate efficacy studies to inform personalized hyperlipidemia treatment
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Fibrate Drugs Market, by Drug Type
8.1. Introduction
8.2. Bezafibrate
8.3. Ciprofibrate
8.4. Fenofibrate
8.5. Gemfibrozil
9. Fibrate Drugs Market, by Formulation
9.1. Introduction
9.2. Capsules
9.3. Oral Suspension
9.4. Tablets
10. Fibrate Drugs Market, by Route Of Administration
10.1. Introduction
10.2. Oral
11. Fibrate Drugs Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Home Care
11.4. Hospitals
11.5. Retail Pharmacies
12. Fibrate Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.3.1. Branded Online
12.3.2. Third-Party Platform
12.4. Retail Pharmacy
12.4.1. Chain Retail Pharmacy
12.4.2. Independent Retail Pharmacy
13. Fibrate Drugs Market, by Dosage Strength
13.1. Introduction
13.2. 100 mg
13.3. 145 mg
13.4. 200 mg
13.5. 48 mg
13.6. 67 mg
14. Fibrate Drugs Market, by Indication
14.1. Introduction
14.2. Hypercholesterolemia
14.3. Hypertriglyceridemia
14.4. Mixed Dyslipidemia
15. Americas Fibrate Drugs Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Fibrate Drugs Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Fibrate Drugs Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Abbott Laboratories
18.3.2. Kowa Pharmaceuticals America, LLC
18.3.3. Teva Pharmaceutical Industries Ltd.
18.3.4. Viatris Inc.
18.3.5. Sandoz International GmbH
18.3.6. Dr. Reddy’s Laboratories Ltd.
18.3.7. Sun Pharmaceutical Industries Ltd.
18.3.8. Lupin Limited
18.3.9. Zydus Lifesciences Ltd.
18.3.10. Torrent Pharmaceuticals Ltd.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. FIBRATE DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL FIBRATE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL FIBRATE DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL FIBRATE DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL FIBRATE DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2030 (%)
FIGURE 16. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. FIBRATE DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. FIBRATE DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. FIBRATE DRUGS MARKET: RESEARCHAI
FIGURE 30. FIBRATE DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 31. FIBRATE DRUGS MARKET: RESEARCHCONTACTS
FIGURE 32. FIBRATE DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. FIBRATE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL FIBRATE DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL FIBRATE DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL FIBRATE DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL FIBRATE DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL FIBRATE DRUGS MARKET SIZE, BY BEZAFIBRATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL FIBRATE DRUGS MARKET SIZE, BY BEZAFIBRATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL FIBRATE DRUGS MARKET SIZE, BY CIPROFIBRATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL FIBRATE DRUGS MARKET SIZE, BY CIPROFIBRATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL FIBRATE DRUGS MARKET SIZE, BY GEMFIBROZIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL FIBRATE DRUGS MARKET SIZE, BY GEMFIBROZIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL FIBRATE DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL FIBRATE DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL FIBRATE DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL FIBRATE DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL FIBRATE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL FIBRATE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL FIBRATE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL FIBRATE DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL FIBRATE DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL FIBRATE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL FIBRATE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL FIBRATE DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL FIBRATE DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL FIBRATE DRUGS MARKET SIZE, BY BRANDED ONLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL FIBRATE DRUGS MARKET SIZE, BY BRANDED ONLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL FIBRATE DRUGS MARKET SIZE, BY THIRD-PARTY PLATFORM, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL FIBRATE DRUGS MARKET SIZE, BY THIRD-PARTY PLATFORM, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL FIBRATE DRUGS MARKET SIZE, BY CHAIN RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL FIBRATE DRUGS MARKET SIZE, BY CHAIN RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL FIBRATE DRUGS MARKET SIZE, BY INDEPENDENT RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL FIBRATE DRUGS MARKET SIZE, BY INDEPENDENT RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL FIBRATE DRUGS MARKET SIZE, BY 100 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL FIBRATE DRUGS MARKET SIZE, BY 100 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL FIBRATE DRUGS MARKET SIZE, BY 145 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL FIBRATE DRUGS MARKET SIZE, BY 145 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL FIBRATE DRUGS MARKET SIZE, BY 200 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL FIBRATE DRUGS MARKET SIZE, BY 200 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL FIBRATE DRUGS MARKET SIZE, BY 48 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL FIBRATE DRUGS MARKET SIZE, BY 48 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL FIBRATE DRUGS MARKET SIZE, BY 67 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL FIBRATE DRUGS MARKET SIZE, BY 67 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL FIBRATE DRUGS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL FIBRATE DRUGS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL FIBRATE DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL FIBRATE DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL FIBRATE DRUGS MARKET SIZE, BY MIXED DYSLIPIDEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL FIBRATE DRUGS MARKET SIZE, BY MIXED DYSLIPIDEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS FIBRATE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 121. CANADA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 122. CANADA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 123. CANADA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 124. CANADA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 125. CANADA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 126. CANADA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 127. CANADA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 128. CANADA FIBRATE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 129. CANADA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 130. CANADA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 131. CANADA FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 132. CANADA FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 133. CANADA FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 134. CANADA FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 135. CANADA FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 136. CANADA FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 137. CANADA FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 138. CANADA FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 139. MEXICO FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 140. MEXICO FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 141. MEXICO FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 142. MEXICO FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 143. MEXICO FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 144. MEXICO FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 145. MEXICO FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. MEXICO FIBRATE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. MEXICO FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. MEXICO FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. MEXICO FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 150. MEXICO FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 151. MEXICO FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 152. MEXICO FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 153. MEXICO FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 154. MEXICO FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 155. MEXICO FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 156. MEXICO FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL FIBRATE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM FIBRATE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 231. GERMANY FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 232. GERMANY FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 233. GERMANY FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 234. GERMANY FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 235. GERMANY FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 236. GERMANY FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 237. GERMANY FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 238. GERMANY FIBRATE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 239. GERMANY FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 240. GERMANY FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 241. GERMANY FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 242. GERMANY FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 243. GERMANY FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 244. GERMANY FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 245. GERMANY FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 246. GERMANY FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 247. GERMANY FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 248. GERMANY FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 249. FRANCE FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 250. FRANCE FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 251. FRANCE FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 252. FRANCE FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 253. FRANCE FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 254. FRANCE FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 255. FRANCE FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 256. FRANCE FIBRATE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 257. FRANCE FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. FRANCE FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. FRANCE FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 260. FRANCE FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 261. FRANCE FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 262. FRANCE FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 263. FRANCE FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 264. FRANCE FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 265. FRANCE FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 266. FRANCE FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 268. RUSSIA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA FIBRATE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 275. RUSSIA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 276. RUSSIA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 277. RUSSIA FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 278. RUSSIA FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 279. RUSSIA FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 280. RUSSIA FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 281. RUSSIA FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 282. RUSSIA FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 283. RUSSIA FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 284. RUSSIA FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 285. ITALY FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 286. ITALY FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 287. ITALY FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 288. ITALY FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 289. ITALY FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 290. ITALY FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 291. ITALY FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 292. ITALY FIBRATE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 293. ITALY FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. ITALY FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. ITALY FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 296. ITALY FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 297. ITALY FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 298. ITALY FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 299. ITALY FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 300. ITALY FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 301. ITALY FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 302. ITALY FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 303. SPAIN FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 304. SPAIN FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 305. SPAIN FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 306. SPAIN FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 307. SPAIN FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 308. SPAIN FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 309. SPAIN FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 310. SPAIN FIBRATE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 311. SPAIN FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 312. SPAIN FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 313. SPAIN FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 314. SPAIN FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 315. SPAIN FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 316. SPAIN FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 317. SPAIN FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 318. SPAIN FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 319. SPAIN FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 320. SPAIN FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 321. UNITED ARAB EMIRATES FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 322. UNITED ARAB EMIRATES FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 323. UNITED ARAB EMIRATES FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 324. UNITED ARAB EMIRATES FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 325. UNITED ARAB EMIRATES FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 326. UNITED ARAB EMIRATES FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 327. UNITED ARAB EMIRATES FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 328. UNITED ARAB EMIRATES FIBRATE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 329. UNITED ARAB EMIRATES FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 330. UNITED ARAB EMIRATES FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 331. UNITED ARAB EMIRATES FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 332. UNITED ARAB EMIRATES FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 333. UNITED ARAB EMIRATES FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 334. UNITED ARAB EMIRATES FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 335. UNITED ARAB EMIRATES FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 336. UNITED ARAB EMIRATES FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 337. UNITED ARAB EMIRATES FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 338. UNITED ARAB EMIRATES FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 339. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 340. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 341. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 342. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 343. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 344. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 345. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 346. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 347. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 348. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 349. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 350. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 351. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 352. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 353. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 354. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 355. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 356. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 357. SOUTH AFRICA FIBRATE DRUGS MARKET SIZE, B

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Fibrate Drugs market report include:
  • Abbott Laboratories
  • Kowa Pharmaceuticals America, LLC
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Sandoz International GmbH
  • Dr. Reddy’s Laboratories Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Limited
  • Zydus Lifesciences Ltd.
  • Torrent Pharmaceuticals Ltd.

Table Information

Report AttributeDetails
No. of Pages182
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.98 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.56 Billion
Compound Annual Growth Rate6.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Atherosclerosis Drugs Market by Drug Class (Bile Acid Sequestrants, Fibrates, Niacin), Administration Route (Injectable, Oral), Distribution Channel, Dosage Form, End User - Global Forecast 2025-2030 - Product Image

Atherosclerosis Drugs Market by Drug Class (Bile Acid Sequestrants, Fibrates, Niacin), Administration Route (Injectable, Oral), Distribution Channel, Dosage Form, End User - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Hyperlipidemia Drugs Market by Drug Class (Bile Acid Sequestrants, Fibrates, Omega-3 Fatty Acids), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End User, Route Of Administration, Patient Type, Hyperlipidemia Type - Global Forecast 2025-2030 - Product Image

Hyperlipidemia Drugs Market by Drug Class (Bile Acid Sequestrants, Fibrates, Omega-3 Fatty Acids), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End User, Route Of Administration, Patient Type, Hyperlipidemia Type - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Fibrate Drugs Market Report 2025 - Product Image

Fibrate Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Severe Hypertriglyceridemia Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Severe Hypertriglyceridemia Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 138 Pages
  • Global
From
Dyslipidemia Market Report 2025 - Product Image

Dyslipidemia Market Report 2025

  • Report
  • 175 Pages
  • Global
From

About the Fibrates Market

Fibrates are a class of drugs used to treat cardiovascular diseases, such as high cholesterol and triglyceride levels. They work by increasing the activity of the enzyme lipoprotein lipase, which helps to break down fats in the blood. Fibrates are often used in combination with statins, another class of drugs used to lower cholesterol levels. Fibrates are generally well tolerated, but can cause side effects such as muscle pain, nausea, and abdominal pain. Fibrates are available in both prescription and over-the-counter forms. Commonly prescribed fibrates include fenofibrate, gemfibrozil, and clofibrate. Over-the-counter fibrates include omega-3 fatty acids, which are found in fish oil supplements. Several companies are involved in the fibrates market, including Pfizer, Merck, GlaxoSmithKline, Sanofi, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.